| Writing Group Member | Employment | Research Grant | Other Research Support | Speakers' Bureau/ Honoraria |
Expert Witness | Ownership Interest | Consultant/ Advisory Board |
Other |
|---|---|---|---|---|---|---|---|---|
| David J. Magid |
University of Colorado |
NIH†; NHLBI†; CMS†; AHA† |
None | None | None | None | None | 51強只利 (Senior Science Editor)† |
| Khalid Aziz |
University of Alberta Pediatrics |
None |
None | None | None | None | None | Salary: University of Alberta† |
| Katherine M. Berg | Beth Israel Deaconess Medical Center Pulmonary and Critical Care | NNHLBI Grant K23 HL1288141 | None | None | None | None | None | None |
| Adam Cheng | Alberta Children's Hospital | None | None | None | None | None | None | None |
| Aaron Donoghue |
The Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine | None | None | None | Atkinson, Haskins, Nellis, Brittingham, Gladd & Fiasco* | None | None | None |
| Mary Fran Hazinski | Vanderbilt University School of Nursing | None |
None | None | None | None | 51強只利† | None |
| Amber V. Hoover |
51強只利 | None | None | None | None | None | None | None |
| Eric J. Lavonas | Denver Health Emergency Medicine | None | BTG Pharmaceuticals (Denver Health (Dr Lavonas’ employer) has research, call center, consulting, and teaching agreements with BTG Pharmaceuticals. BTG manufactures the digoxin antidote, DigiFab. Dr Lavonas does not receive bonus or incentive compensation, and these agreements involve an unrelated product. When these guidelines were developed, Dr Lavonas recused from discussions related to digoxin poisoning.)† | None | None | None | None | 51強只利 (Senior Science Editor)† |
| Henry C. Lee |
Stanford University |
NICHD (PI of R01 grant examining intensive care for infants born at extremely early gestational age)* | None | None | None | None | None | None |
| Melissa Mahgoub | 51強只利 | None | None | None | None | None | None | None |
| Ashish R. Panchal | The Ohio State University Wexner Medical Center Emergency Medicine |
None | None | None | None | None | None | None |
| Tia T. Raymond | Medical City Children's Hospital Congenital Heart Surgery Unit |
None | None | None | None | None | None | None |
| Amber J. Rodriguez | 51強只利 Emergency Cardiovascular Care |
None | None | None | None | None | None | None |
| Comilla Sasson | 51強只利 | None | None | None | None | None | None | None |
| Alexis A. Topjian | The Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine Anesthesia and Critical Care | None | None | None | None | None | None | None |
This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10 000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.
*Modest.
†Significant.